Media coverage about Kadmon (NYSE:KDMN) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Kadmon earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.0945539029427 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
KDMN stock traded up $0.17 during mid-day trading on Wednesday, reaching $4.42. 68,047 shares of the company were exchanged, compared to its average volume of 1,072,183. Kadmon has a one year low of $2.05 and a one year high of $5.86. The firm has a market cap of $333.45, a PE ratio of -2.85 and a beta of 5.59.
Kadmon (NYSE:KDMN) last posted its quarterly earnings results on Tuesday, March 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.12. The business had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $3.07 million. During the same period in the prior year, the business posted ($0.50) earnings per share. The business’s quarterly revenue was down 65.1% compared to the same quarter last year. sell-side analysts predict that Kadmon will post -1.11 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Kadmon (NYSE:KDMN) Share Price” was originally posted by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://baseballnewssource.com/2018/03/21/kadmon-kdmn-getting-somewhat-positive-media-coverage-accern-reports/2028660.html.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.